Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Cladribine
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Mitoxantrone for multiple sclerosis.
Generic interferon-beta
Daclizumab for relapsing remitting multiple sclerosis.

Pages